May 24, 2017
FDA Advisory Committee recommends approval of Emmaus Life Sciences’s sickle cell disease drug
The Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10 to 3 that the overall Benefit-Risk profile of Emmaus Life Sciences’s Endari for the treatment of sickle cell disease (SCD) is favorable.